Edwards Lifesciences (EW) Long-Term Investments (2009 - 2026)

Edwards Lifesciences' Long-Term Investments history runs 18 years deep, the most recent figure standing at $285.6 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 2.77% year-over-year to $285.6 million; the TTM figure through Mar 2026 stood at $285.6 million (up 2.77% YoY), while the FY2025 annual figure was $278.6 million, down 9.52% from the prior year.
• Long-Term Investments was $285.6 million for Q1 2026 at Edwards Lifesciences, up from $278.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $1.6 billion in Q1 2022 to a low of $274.7 million in Q3 2025.
• Historically, Long-Term Investments has averaged $694.0 million across 5 years, with a median of $455.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Long-Term Investments jumped 102.41% in 2022, then plunged 58.74% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $1.2 billion in 2022, then plunged by 52.87% to $583.9 million in 2023, then sank by 47.27% to $307.9 million in 2024, then retreated by 9.52% to $278.6 million in 2025, then climbed by 2.51% to $285.6 million in 2026.
• The last three Long-Term Investments figures came in at $285.6 million (Q1 2026), $278.6 million (Q4 2025), and $274.7 million (Q3 2025), per Business Quant data.